

# Lars G Hemkens

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4044741/publications.pdf>

Version: 2024-02-01

111  
papers

7,607  
citations

126708

33  
h-index

58464

82  
g-index

128  
all docs

128  
docs citations

128  
times ranked

12422  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reporting transparency and completeness in trials: Paper 1: Introduction - Better reporting for disruptive clinical trials using routinely collected data. <i>Journal of Clinical Epidemiology</i> , 2022, 141, 172-174.	2.4	5
2	Reporting transparency and completeness in Trials: Paper 2 - reporting of randomised trials using registries was often inadequate and hindered the interpretation of results. <i>Journal of Clinical Epidemiology</i> , 2022, 141, 175-186.	2.4	8
3	Reporting transparency and completeness in trials: Paper 4 - reporting of randomised controlled trials conducted using routinely collected electronic records – room for improvement. <i>Journal of Clinical Epidemiology</i> , 2022, 141, 198-209.	2.4	7
4	Reporting transparency and completeness in trials: Paper 3 – trials conducted using administrative databases do not adequately report elements related to use of databases. <i>Journal of Clinical Epidemiology</i> , 2022, 141, 187-197.	2.4	7
5	Randomized trials on non-pharmaceutical interventions for COVID-19: a scoping review. <i>BMJ Evidence-Based Medicine</i> , 2022, 27, 334-344.	1.7	22
6	Nonregistration, discontinuation, and nonpublication of randomized trials: A repeated meta-research analysis. <i>PLoS Medicine</i> , 2022, 19, e1003980.	3.9	21
7	Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152017.	1.6	32
8	Searching two or more databases decreased the risk of missing relevant studies: a meta-research study. <i>Journal of Clinical Epidemiology</i> , 2022, 149, 154-164.	2.4	18
9	Ten simple rules for good research practice. <i>PLoS Computational Biology</i> , 2022, 18, e1010139.	1.5	12
10	Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs. <i>JAMA Network Open</i> , 2021, 4, e210380.	2.8	8
11	Treatment effects in randomised trials using routinely collected data for outcome assessment versus traditional trials: meta-research study. <i>BMJ, The</i> , 2021, 372, n450.	3.0	27
12	Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1185.	3.8	209
13	Recruitment and Results Reporting of COVID-19 Randomized Clinical Trials Registered in the First 100 Days of the Pandemic. <i>JAMA Network Open</i> , 2021, 4, e210330.	2.8	19
14	CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. <i>BMJ, The</i> , 2021, 373, n857.	3.0	65
15	Methods and results used in the development of a consensus-driven extension to the Consolidated Standards of Reporting Trials (CONSORT) statement for trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE). <i>BMJ Open</i> , 2021, 11, e049093.	0.8	9
16	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. <i>Nature Communications</i> , 2021, 12, 2349.	5.8	194
17	Randomized COVID-19 vaccination rollout can offer direct real-world evidence. <i>Journal of Clinical Epidemiology</i> , 2021, 138, 199-202.	2.4	5
18	Reporting quality of trial protocols improved for non-regulated interventions but not regulated interventions: A repeated cross-sectional study. <i>Journal of Clinical Epidemiology</i> , 2021, 139, 340-349.	2.4	7

#	ARTICLE	IF	CITATIONS
19	A study protocol for the development of a SPIRIT extension for trials conducted using cohorts and routinely collected data (SPIRIT-ROUTINE). HRB Open Research, 2021, 4, 82.	0.3	4
20	Challenges and Lessons Learned From COVID-19 Trials: Should We Be Doing Clinical Trials Differently?. Canadian Journal of Cardiology, 2021, 37, 1353-1364.	0.8	34
21	A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®. Trials, 2021, 22, 724.	0.7	9
22	Evaluation of Planned Subgroup Analysis in Protocols of Randomized Clinical Trials. JAMA Network Open, 2021, 4, e2131503.	2.8	2
23	Reliability of Trial Information Across Registries for Trials With Multiple Registrations. JAMA Network Open, 2021, 4, e2128898.	2.8	12
24	Barriers and Facilitating Factors for Conducting Systematic Evidence Assessments in Academic Clinical Trials. JAMA Network Open, 2021, 4, e2136577.	2.8	7
25	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. BMC Infectious Diseases, 2021, 21, 1170.	1.3	46
26	Prepectoral versus subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02/ PREPEC): a pragmatic, multicentre, randomised, superiority trial. BMJ Open, 2021, 11, e045239.	0.8	12
27	A scoping review shows that several nonvalidated budget planning tools for randomized trials are available. Journal of Clinical Epidemiology, 2020, 117, 9-19.	2.4	5
28	Nonrandomized studies using causal-modeling may give different answers than RCTs: a meta-epidemiological study. Journal of Clinical Epidemiology, 2020, 118, 29-41.	2.4	13
29	Consideration of confounding was suboptimal in the reporting of observational studies in psychiatry: a meta-epidemiological study. Journal of Clinical Epidemiology, 2020, 119, 75-84.	2.4	20
30	Oral corticosteroids for post-infectious cough in adults: study protocol for a double-blind randomized placebo-controlled trial in Swiss family practices (OSPIC trial). Trials, 2020, 21, 949.	0.7	0
31	Knowledge gaps in oncoplastic breast surgery. Lancet Oncology, The, 2020, 21, e375-e385.	5.1	34
32	Abbreviated and comprehensive literature searches led to identical or very similar effect estimates: a meta-epidemiological study. Journal of Clinical Epidemiology, 2020, 128, 1-12.	2.4	13
33	Characteristics and interpretation of subgroup analyses based on tumour characteristics in randomised trials testing target-specific anticancer drugs: design of a systematic survey. BMJ Open, 2020, 10, e034565.	0.8	0
34	Prediction of RECRUITment In randomized clinical Trials (RECRUIT-IT)â€™ rationale and design for an international collaborative study. Trials, 2020, 21, 731.	0.7	10
35	Patient involvement to inform the design of a clinical trial in postbariatric hypoglycaemia. BMC Medical Research Methodology, 2020, 20, 290.	1.4	1
36	Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. JAMA Network Open, 2020, 3, e2024406.	2.8	53

#	ARTICLE	IF	CITATIONS
37	Online randomized controlled experiments at scale: lessons and extensions to medicine. <i>Trials</i> , 2020, 21, 150.	0.7	19
38	Commentary on Bertagnolli et al: Clinical trial designs with routinely collected real-world data—issues of data quality and beyond. <i>Clinical Trials</i> , 2020, 17, 247-250.	0.7	3
39	Rationale and design of repeated cross-sectional studies to evaluate the reporting quality of trial protocols: the Adherence to SPIrit REcommendations (ASPIRE) study and associated projects. <i>Trials</i> , 2020, 21, 896.	0.7	9
40	The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. <i>F1000Research</i> , 2020, 9, 1193.	0.8	41
41	The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. <i>F1000Research</i> , 2020, 9, 1193.	0.8	38
42	Rituximab in primary central nervous system lymphoma—A systematic review and meta-analysis. <i>Hematological Oncology</i> , 2019, 37, 548-557.	0.8	54
43	Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies. <i>Journal of Clinical Epidemiology</i> , 2019, 114, 49-59.	2.4	20
44	Effect of Combination <scp></scp>-Citrulline and Metformin Treatment on Motor Function in Patients With Duchenne Muscular Dystrophy. <i>JAMA Network Open</i> , 2019, 2, e1914171.	2.8	34
45	Using electronic health records for clinical trials: Where do we stand and where can we go?. <i>Cmaj</i> , 2019, 191, E128-E133.	0.9	44
46	Single-dose versus 3-day cotrimoxazole prophylaxis in transurethral resection or greenlight laser vaporisation of the prostate: study protocol for a multicentre randomised placebo controlled non-inferiority trial (CITrUS trial). <i>Trials</i> , 2019, 20, 142.	0.7	2
47	Current use and costs of electronic health records for clinical trial research: a descriptive study. <i>CMAJ Open</i> , 2019, 7, E23-E32.	1.1	44
48	32—Open access budget tools for the planning of randomised controlled trials: a scoping review. , 2019, , .		0
49	Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. <i>ESMO Open</i> , 2019, 4, e000596.	2.0	4
50	Dopaminergic agents versus control for enhancing stroke recovery and rehabilitation. <i>The Cochrane Library</i> , 2019, , .	1.5	1
51	OFF-LABEL USE IN LYMPHOMA PATIENTS IN SWITZERLAND. <i>Hematological Oncology</i> , 2019, 37, 537-538.	0.8	4
52	Marginal structural models and other analyses allow multiple estimates of treatment effects in randomized clinical trials: Meta-epidemiological analysis. <i>Journal of Clinical Epidemiology</i> , 2019, 107, 12-26.	2.4	8
53	Resource use, costs, and approval times for planning and preparing a randomized clinical trial before and after the implementation of the new Swiss human research legislation. <i>PLoS ONE</i> , 2019, 14, e0210669.	1.1	10
54	Systematic review and simulation study of ignoring clustered data in surgical trials. <i>British Journal of Surgery</i> , 2018, 105, 182-191.	0.1	6

#	ARTICLE	IF	CITATIONS
55	Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials. <i>Journal of Clinical Epidemiology</i> , 2018, 94, 35-45.	2.4	11
56	Systematic review on costs and resource use of randomized clinical trials shows a lack of transparent and comprehensive data. <i>Journal of Clinical Epidemiology</i> , 2018, 96, 1-11.	2.4	77
57	Retrospective assessment of resource use and costs in two investigator-initiated randomized trials exemplified a comprehensive cost item list. <i>Journal of Clinical Epidemiology</i> , 2018, 96, 73-83.	2.4	15
58	Interpretation of epidemiologic studies very often lacked adequate consideration of confounding. <i>Journal of Clinical Epidemiology</i> , 2018, 93, 94-102.	2.4	40
59	Protocol for the development of a CONSORT extension for RCTs using cohorts and routinely collected health data. <i>Research Integrity and Peer Review</i> , 2018, 3, 9.	2.2	28
60	The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). <i>BMJ: British Medical Journal</i> , 2018, 363, k3532.	2.4	268
61	How Routinely Collected Data for Randomized Trials Provide Long-term Randomized Real-World Evidence. <i>JAMA Network Open</i> , 2018, 1, e186014.	2.8	20
62	The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs. <i>Trials</i> , 2018, 19, 505.	0.7	17
63	Treatments for subacute cough in primary care: systematic review and meta-analyses of randomised clinical trials. <i>British Journal of General Practice</i> , 2018, 68, e694-e702.	0.7	14
64	Abbreviated literature searches were viable alternatives to comprehensive searches: a meta-epidemiological study. <i>Journal of Clinical Epidemiology</i> , 2018, 102, 1-11.	2.4	53
65	How to use FDA drug approval documents for evidence syntheses. <i>BMJ: British Medical Journal</i> , 2018, 362, k2815.	2.4	17
66	Routinely collected data for randomized trials: promises, barriers, and implications. <i>Trials</i> , 2018, 19, 29.	0.7	98
67	Protocol for a scoping review to support development of a CONSORT extension for randomised controlled trials using cohorts and routinely collected health data. <i>BMJ Open</i> , 2018, 8, e025266.	0.8	10
68	Off-label prescription: experience is a gloomy lantern that does not even illuminate its bearer. Author response. <i>Journal of Clinical Epidemiology</i> , 2018, 101, 127-128.	2.4	0
69	Niacin for primary and secondary prevention of cardiovascular events. <i>The Cochrane Library</i> , 2017, 2017, CD009744.	1.5	43
70	Premature Discontinuation of Pediatric Randomized Controlled Trials: A Retrospective Cohort Study. <i>Journal of Pediatrics</i> , 2017, 184, 209-214.e1.	0.9	23
71	Personalized Prescription Feedback Using Routinely Collected Data to Reduce Antibiotic Use in Primary Care. <i>JAMA Internal Medicine</i> , 2017, 177, 176.	2.6	76
72	Comparative effectiveness of tenofovir in HIV-infected treatment-experienced patients: systematic review and meta-analysis. <i>HIV Clinical Trials</i> , 2017, 18, 17-27.	2.0	9

#	ARTICLE	IF	CITATIONS
73	Quality of antibiotic prescribing of Swiss primary care physicians with high prescription rates: a nationwide survey. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3205-3212.	1.3	26
74	Towards the development of a comprehensive framework: Qualitative systematic survey of definitions of clinical research quality. <i>PLoS ONE</i> , 2017, 12, e0180635.	1.1	6
75	Agreements between Industry and Academia on Publication Rights: A Retrospective Study of Protocols and Publications of Randomized Clinical Trials. <i>PLoS Medicine</i> , 2016, 13, e1002046.	3.9	20
76	Premature Discontinuation of Randomized Trials in Critical and Emergency Care. <i>Critical Care Medicine</i> , 2016, 44, 130-137.	0.4	28
77	Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis. <i>Heart</i> , 2016, 102, 590-596.	1.2	48
78	Better research reporting to improve the utility of routine data for making better treatment decisions. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 117-122.	0.6	2
79	Personalized prescription feedback to reduce antibiotic overuse in primary care: rationale and design of a nationwide pragmatic randomized trial. <i>BMC Infectious Diseases</i> , 2016, 16, 421.	1.3	15
80	The reporting of studies using routinely collected health data was often insufficient. <i>Journal of Clinical Epidemiology</i> , 2016, 79, 104-111.	2.4	51
81	Colchicine and Prevention of Cardiovascular Events. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1106.	3.8	6
82	Authors' reply to Pärrol and colleagues. <i>BMJ, The</i> , 2016, 355, i6747.	3.0	0
83	Current use of routinely collected health data to complement randomized controlled trials: a meta-epidemiological survey. <i>CMAJ Open</i> , 2016, 4, E132-E140.	1.1	19
84	Colchicine for prevention of cardiovascular events. <i>The Cochrane Library</i> , 2016, , CD011047.	1.5	45
85	Routinely collected data and comparative effectiveness evidence: promises and limitations. <i>Cmaj</i> , 2016, 188, E158-E164.	0.9	125
86	Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey. <i>BMJ, The</i> , 2016, 352, i493.	3.0	133
87	An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules. <i>Journal of Clinical Epidemiology</i> , 2016, 69, 152-160.	2.4	19
88	Completion and Publication Rates of Randomized Controlled Trials in Surgery. <i>Annals of Surgery</i> , 2015, 262, 68-73.	2.1	45
89	The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. <i>PLoS Medicine</i> , 2015, 12, e1001885.	3.9	2,892
90	Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis. <i>HIV Clinical Trials</i> , 2015, 16, 178-189.	2.0	22

#	ARTICLE	IF	CITATIONS
91	Association between Ambient Air Pollution and Diabetes Mellitus in Europe and North America: Systematic Review and Meta-Analysis. <i>Environmental Health Perspectives</i> , 2015, 123, 381-389.	2.8	423
92	Planning and reporting of quality-of-life outcomes in cancer trials. <i>Annals of Oncology</i> , 2015, 26, 1966-1973.	0.6	47
93	Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications. <i>BMJ, The</i> , 2014, 349, g4539-g4539.	3.0	74
94	Prevalence, Characteristics, and Publication of Discontinued Randomized Trials. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1045.	3.8	265
95	Clinical effectiveness of stress-reduction techniques in patients with hypertension. <i>Journal of Hypertension</i> , 2014, 32, 1936-1944.	0.3	41
96	HIV infection and cardiovascular disease. <i>European Heart Journal</i> , 2014, 35, 1373-1381.	1.0	198
97	Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications. <i>BMJ, The</i> , 2014, 349, g4921-g4921.	3.0	5
98	Increasing Physical Activity for the Treatment of Hypertension: A Systematic Review and Meta-Analysis. <i>Sports Medicine</i> , 2013, 43, 1009-1023.	3.1	80
99	Concordance of effects of medical interventions on hospital admission and readmission rates with effects on mortality. <i>Cmaj</i> , 2013, 185, E827-E837.	0.9	5
100	All Nations Depend on the Global Knowledge Pool – Analysis of Country of Origin of Studies Used for Health Technology Assessments in Germany. <i>PLoS ONE</i> , 2013, 8, e59213.	1.1	4
101	Self-management of oral anticoagulation in elderly patients – Effects on treatment-related Quality of Life. <i>Thrombosis Research</i> , 2012, 130, e60-e66.	0.8	13
102	Benefit assessment of salt reduction in patients with hypertension: systematic overview. <i>Journal of Hypertension</i> , 2011, 29, 821-828.	0.3	35
103	Low-dose rate brachytherapy for men with localized prostate cancer. <i>The Cochrane Library</i> , 2011, , CD008871.	1.5	29
104	Long-term effects of weight-reducing diets in hypertensive patients. , 2011, , CD008274.		64
105	Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues. Reply to Nagel JM, Mansmann U, Wegscheider K et al. [letter] and Simon D [letter]. <i>Diabetologia</i> , 2010, 53, 209-211.	2.9	15
106	Insufficient evaluation of adverse events is not a proof of safety. <i>Diabetologia</i> , 2010, 53, 790-792.	2.9	7
107	Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. <i>Diabetologia</i> , 2009, 52, 1732-1744.	2.9	548
108	Insulin glargine and cancer. <i>Lancet, The</i> , 2009, 374, 1743-1744.	6.3	13

#	ARTICLE	IF	CITATIONS
109	A randomized trial comparing INR monitoring devices in patients with anticoagulation self-management: evaluation of a novel error-grid approach. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 26, 22-30.	1.0	15
110	Comparison of Negative Pressure Wound Therapy Using Vacuum-Assisted Closure With Advanced Moist Wound Therapy in the Treatment of Diabetic Foot Ulcers: A Multicenter Randomized Controlled Trial. <i>Diabetes Care</i> , 2008, 31, e76-e76.	4.3	5
111	Clinical trial research on COVID-19 in Germany â€” a systematic analysis. <i>F1000Research</i> , 0, 10, 913.	0.8	5